VISEN Pharmaceuticals Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-182.24	-249.57	-288.97
Depreciation & Amortization	3.95	6.15	6.67
Other Amortization	0.51	0.85	0.72
Loss (Gain) From Sale of Assets	-	0.24	0.09
Stock-Based Compensation	32.77	-12.27	93.51
Other Operating Activities	2.48	67.12	-0.77
Change in Accounts Payable	1.21	-12.08	4.44
Change in Unearned Revenue	-2.9	-	-
Change in Other Net Operating Assets	3.36	-71.75	-62.25
Operating Cash Flow	-140.86	-271.31	-246.55
Capital Expenditures	-0.12	-0.52	-1.48
Sale (Purchase) of Intangibles	-	-	-0.28
Investing Cash Flow	-0.12	-0.52	-1.77
Long-Term Debt Repaid	-3.09	-4.95	-5.78
Net Debt Issued (Repaid)	-3.09	-4.95	-5.78
Other Financing Activities	-	-2.01	-2.17
Financing Cash Flow	-3.09	-6.95	-7.95
Foreign Exchange Rate Adjustments	-0.13	0.11	0.07
Net Cash Flow	-144.2	-278.68	-256.2
Free Cash Flow	-140.98	-271.83	-248.03
Free Cash Flow Margin	-5076.52%	-	-
Free Cash Flow Per Share	-1.51	-2.90	-
Levered Free Cash Flow	-63.57	-67.66	-
Unlevered Free Cash Flow	-63.47	-67.46	-
Change in Working Capital	1.66	-83.83	-57.81

Source: S&P Global Market Intelligence. Standard template. Financial Sources.